A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 16 Apr 2026
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 16 Apr 2026 New trial record